The FreeMind Group is the premier international consulting firm specializing in assisting life science organizations secure non-dilutive funding from US Federal Agencies and Private Foundations
New York, NY
New York, NY
La Jolla, CA
Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. Our goal is to assist in maximizing potential to receive funding from non-dilutive sources. We have experience in seeking funding from nearly all NIH Institutes, Department of Defense, NSF, FDA, BARDA, etc., as well as private foundations.
FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our expertise in applying for grants and contracts extends throughout every government mechanism as well as private foundations open to funding the life sciences.
FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date. Awards range from $150,000 to $100,000,000 per project. Our team of experts will assist in making non-dilutive funding a key tool in a long-term sound financial strategy.
FreeMind did unbelievable job- and put in so many hrs today and all throughout the past few weeks. I don’t think we could have done it without such help from FreeMind and all of you!
Many thanks for your excellent support. It was and continues to be our pleasure working with you, and we too look forward to embarking on a new grant project with you again soon.
Thank you all for your tireless, persistent efforts in pushing this through. We are now well positioned to let the considerable merits of our application shine through. Much appreciated.
From the Immusoft, Thank you again for your efforts and guidance during the assemblage of our SBIR grant. We have improved our grantsmanship as a result of FMG’s involvement.
There is no way we would have been able to do it in such a short time without you.
Thank you for all your help!!!
After a powerful joint effort as usual, and many careful iterations of edits, this proposal looks top-notch! Thanks to all for your participation in the success of this submission. Thank you Freemind, in particular, your hard work has greatly improved this proposal, you have been a tremendous help, right up to the end.
Thank you very much. Writing this grant proposal has been very insightful to me, and the Freemind team made it a very smooth process.
I LOVE working with you guys!! ……..Your true entrepreneurial approach is just what I needed right now…….
FreeMind has added a lot of value to the proposal, driving us perfectly through the process, the exact role we were expecting
We are very satisfied with the role and involvement of FreeMind on our project. All has been submitted on time with a great interaction (and hard work) between our two teams.
Thanks so much for all of your help on this proposal! I am so grateful that you were available to work with us, and I don’t think we could have done it without you.
You did a fantastic job for Embolx and I continue to recommend FreeMind to entrepreneurs here is Silicon Valley.
FreeMind’s professional staff has assisted in attaining funding for R&D activities from all available sources and mechanisms stemming primarily from the National Institutes of Health (NIH) as well as Department of Defense (DoD).
We have helped organizations across the life sciences secure funding from these zero-equity sources. We have worked with many academic institutions, as well as industry members from small start-ups through large pharmaceutical companies.
Multidisciplinary grants and contracts available for pre-clinical as well as clinical stage research with budgets of $10 million – $150 million per project
Small Business Research and Development grants can be budgeted $150,000 for SBIR/STTR Phase I awards and up to $2 million for SBIR/STTR Phase II awards.
UO1s, BAAs, RFPs implemented science and developmental awards with budgets of $3 million – $7 million per project
Basic research, preclinical, and unsolicited grants focusing on early as well as late-stage preclinical research and can be budgeted $1 million – $3 million per project
This step is designed to provide a robust, long-term, multi-submission strategy for each pipeline project. FreeMind is well versed in the interests, goals and agendas of each NIH Institute. We review the suitability of a proposed project, taking into consideration the significance to public health, innovative factor, strength of research approach, and specific concerns regarding the nature of the project
First, we outline the specific aims and scope of work. Next, the size of the budget is set, and collaborators, subcontractors, and consultants needed for a complete and rounded project are delineated. We devise a timeline and an orderly division of responsibilities in order to facilitate a timely and thorough completion of tasks
Project managers draft comprehensive templates. From this point, the writing effort is combined and is largely based on on-going feedback, comments and edits inserted by the project managers and in response to portions implemented by the client. The iterative review concludes when a well structured scientifically sound application with all items accounted for materializes.
After extensive editing and formatting, the application is ready for submission. Post-submission, project managers track the application and when applicable assists in the award negotiation phase. FreeMind closely follows all deadlines for supplementary data, study section reviews, and final decision by the granting agency
FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award
Non Dilutive Funding – Non di-lu’-tive Fund-ing
1. funding – financial resources provided to make some project possible; “the National Institute of Health (NIH) provided support for the experiment”
2. non-dilutive funding – the act of financing R&D activity not traded for public securities and/or shares of a commercial entity; “The FreeMind Group assisted in securing non-dilutive funding from the Department of Defense for a Phase II clinical trial”
SBIR/STTR Funding; Driving Innovation through Non-Dilutive Sources
SBIR/STTR awards account for over $780,000,000 awarded per year by NIH alone. These are excellent sources of funding aimed at promoting R&D activities of small businesses as well as collaborations with Academics.
SBIR/STTRs differ from traditional NIH mechanisms in that they are highly product driven and ultimately are seeking commercialization of novel therapies, diagnostics, devices, etc.
In this webinar we will discuss process for applying, guidelines, key success components and insight into increasing chances for award.
Funding beyond the SBIR/STTR; RO1s and R21s for Companies
Every year NIH alone awards over $120,000,000 via R’-Mechanisms, among them the RO1 or R21. In order to maximize your funding potential all sources of funding must be considered including the less traditional sources.
R21s aim to fund very early stage proof of concept type programs of up to 2 years at about $300,000, whereas RO1s are more suitable for longer programs of up to 5 years, totaling some $3,000,000.
In this webinar FreeMind experts will share insight into alternatives to the classic SBIR/STTR mechanisms. We will discuss methodology for establishing both responsiveness as well as competitiveness and how to increase chances for award.
Biodefense and Infectious Diseases Non-dilutive Funding
The National Institute of Allergies and Infectious Diseases (NIAID) awards close to $6,000,000,000 annually. Taking into account activities by DTRA, DARPA, US Army, BARDA etc. this is a funding force no one in the field can afford to ignore.
Listen to FreeMind experts share insights into these tremendous sources of funding and get tips on how to maximize potential to receive an award.
Non-Dilutive funding for Non-US applicants
Non-US applicants are eligible for the majority of the non-dilutive pockets of money including NIH, Department of Defense, BARDA etc. Currently, the National Institutes of Health (NIH) are actively funding over 1000 projects in the excess of $1.3B, taking place outside the US and awarded to non-US applicant organizations. And, when taking into account collaborations and partnerships between domestic and foreign entities, the funded R&D dollars outside the US even exceed the above.
In this presentation we will provide insight into the non-dilutive funding landscape with an emphasis on the NIH, Department of Defense and other government agencies. FreeMind experts will describe the various pockets of money available for non-US applicants, potential for funding, and means to maximize chances for award.
U-Mechanism; Cooperative Agreements
The U-Mechanism is a support mechanism used when there will be substantial Federal scientific or programmatic involvement by granting agency. Substantial involvement means that, after award, scientific or program staff will assist, guide, coordinate, or participate in project activities.
We are seeing many programs utilizing this type of mechanism, with substantial awards being made to industry as well.
In this webinar we will discuss process for applying, guidelines, key success components, and insight into increasing chances for award when pursuing U-based opportunities
Medical Device Non-Dilutive Funding: Trends & Opportunities
In a world in which both medical diagnostics and therapies are shifting towards minimally invasive technologies, it is not surprising that steadily increasing non-dilutive funding is available for innovative medical device companies.
The scope of funding support covers the entire R&D cycle, from early stage exploratory and discovery work all the way to late stage clinical research and validation.
In the webinar in the series of summer educational webinars FreeMind experts will discuss the latest trends at the NIH and the new available funding opportunities with respect to medical devices.
CNS/PNS Related Non-Dilutive Funding Opportunities
Within the non-dilutive funding space one can find pockets of money in the billions of dollars directed at unmet medical needs related to CNS/PNS ailments. The scope of funding support covers much of the R&D cycle from proof of concept to late stage clinical.
In the webinar in the series of summer educational webinars FreeMind experts will discuss key CNS/PNS related funding opportunities, with an emphasis on NINDS, NIA, and NIMH.
Cancer Non-dilutive Funding
NIH alone awards roughly $6B annually to Cancer related R&D grants and contracts. The scope of funding support covers much of the R&D cycle with an emphasis on pre-clinical work, and may cover clinical stage activities as well.
In the upcoming webinar in the series of summer educational webinars FreeMind experts will discuss key cancer related opportunities, mainly within the National Cancer Institute (NCI), that are available for Life Science organizations.
The webinars are designed for first timers as well as seasoned grantees. FreeMind experts will share their insight into various areas of interest as they relate to non-dilutive sources of funding and how to maximize chances for award.
For any inquiries, please email Carla Hamoy: Send Mail
423 Brookline Ave. #124
Boston, MA 02215
Tel: (617) 648-0340
Fax: (617) 904-1767
Hi – Tech Center
Jerusalem 95702 Israel
Tel: +972 (0)2-6799833
Fax: +972 (0)2-6799834
Join life science industry leaders in a full day of non-dilutive funding activities at the 11th Annual Non-dilutive Funding Summit, taking place on Wednesday January 13th, 2016 in San Francisco.
This year the summit is proud to host Colonel Russell E. Coleman, Ph.D., Joint Project Manager, Medical Countermeasure Systems Assistant Corps Chief (Medical Service Corps) for Preventive Medicine Entomology. Colonel Coleman will discuss “The Dilemma in the Development of Medical Countermeasures against Chemical and Biological Weapons: An unpredictable threat and products we hope will never be used.”
Attend presentations and panel discussions featuring representatives from NIAID, NIBIB, National MS Society, and the Michael J. Fox Foundation. Also presenting is Ram May-Ron, Managing Partner, FreeMind Group who will provide FreeMind’s annual outlook at the non-dilutive funding landscape; trends and opportunities.
See full agenda for details on all the activities during the day.
Jet setting Life Science Executives looking to maximize their R&D funding potential through zero-equity sources.
Dr Inna Grodzovski, Ph.D
Senior Analyst, FreeMind Group
In the pre-conference workshop FreeMind experts will describe how to plan and execute on a winning multi-submission granting strategy. We will discuss how to outline the significance and innovative aspects, construct specific aims, define quantitative milestones, and comprise a high-level work plan as it relates to NIH specific guidelines, be it budgetary limitations or allowed scope of work.
Ram May-Ron, Managing Partner, FreeMind Group
The R&DMoneyView is an online tool that enables easy access to pertinent information allowing life science executives make informed decisions on how to approach the largest pocket of funding in the world.
The data displayed is carefully collected and analyzed from open Federal data bases by experts from the research arm of the FreeMind Group. All data pertains to domestic life science for-profit organizations.
Ayal Ronen, Vice President, FreeMind Group
The Office of Translational Research (OTR) at the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, facilitates the preclinical discovery and development of new therapeutic interventions for neurological disorders. The OTR offers five programs that support the design, implementation, and management of research activities to critical translational challenges in neurology. The programs include: 1) the Anticonvulsant Screening Program (ASP), 2) Blueprint Network (BPN), 3) The Countermeasures Against Chemical Threats Program (CA), 4) Cooperative Research to Enable and Advance Translational Enterprises (CREATE), and 5) The Small Business Innovation Research Program (SBIR). The OTR provides funding (approximately $100 million annually) in grants and resources to industry and university researchers to advance early-stage neurological technologies, devices, and therapeutic programs to industry adoption (i.e., investor funding and corporate partnerships). Significant emphasis is placed on engaging other stakeholders, such as pharmaceutical, biotechnology, venture capital, and patient advocacy organizations to ensure that projects are adequately de-risked to accelerate downstream investments and to develop much-needed therapies for people suffering from neurological disorders. The keynote talk will provide overiews on these programs and how they can link to successful development outcomes. This will be an excellent opportunity to better understand how to successfully navigate the application process and learn about organizations that have advanced projects using NINDS support. We will also provide information on our funded programs and work with potential interested parties to make the appropriate introductions to our funded investigators.
Russell E. Coleman, Ph.D. COL, MS – Joint Project Manager, Medical Countermeasure Systems Assistant Corps Chief (Medical Service Corps) for Preventive Medicine Entomology Consultant to The Surgeon General
A proven executive with over 25 years leadership experience within the U.S. military. COL Coleman currently serves as the Commander/CEO of the Department of Defense’s advanced development program responsible for developing medical countermeasures to protect our military forces from Chemical and Biological threats, while in his previous assignment he served as Commander/CEO of the Army organization developing and fielding medical countermeasures against all threats.
Presenter: Dr Mike Kurilla – Director, Office of BioDefense, Research Resources, and Translational Research Associate Director for BioDefense Product Development, DMID, NIAID, NIH, DHHS
Following the presentations by Colonel Russell Coleman, US Army, and Dr Michael Kurilla from NIAID, we will breakout into round table discussions where you can discuss in a more relaxed environment specific funding opportunities and gauge the level of interest.
Presenter: Jak Knowles, MD – Managing Director, Vice President Medical and Scientific Affairs
Presenter: Dennis Ford – Founder and CEO, Life Science Nation
Dennis Ford is an entrepreneur and author with expertise in sales, marketing, and business development. He has spent most of his career launching new companies. Over the last decade, he has worked extensively with global alternative investors interested in high-growth early-stage technologies. His expertise encompasses using database subscription services to create business solutions and using the Internet to create an interactive dialog between buyers and sellers. He is a big proponent of using profiling and matching technology to find that all-important business fit in the marketing and selling process. Before LSN, Dennis was the President and CEO of Brighton House Associates (BHA). BHA was launched in order to improve the way hedge fund and private equity fund managers raised capital and marketed their funds to investors.
Ford is the author of The Peddler’s Prerogative and The Fund Manager’s Marketing Manifesto, two well-received sales and marketing books. His latest book is The Life Science Executive’s Fundraising Manifesto. Ford teaches Entrepreneurship Sales & Marketing to undergraduate and graduate students at the University of Massachusetts Boston.
Presenter: Dr Mark Allegretta, Associate VP, Commercial Research, National Multiple Sclerosis Society
Presenter: Evelia Johnston – Research Partnerships Officer at The Michael J. Fox Foundation for Parkinson’s Research
Presenter: Todd Merchak, Biomedical Engineer in the Extramural Science Program at the NIBIB
Ayal Ronen, FreeMind Group
Colonel Russell E. Coleman – DOD
Dr Mike Kurilla – NIAID
Dr Mark Allegretta – MS Society
Evelia Johnston – MJFF
Natalie Wisniewski – Profusa, Inc.
Todd Merchak – NIBIB
The Non-Dilutive Funding Summit will culminate with this exciting panel bringing together representatives from the presenting funding agencies to discuss strategy, policy and overall best practices and expectations for Industry.
Alitair Pharmaceuticals, Inc
AptamiR Therapeutics, Inc
Arno Therapeutics, Inc.
Autonomic Technologies, Inc. (ATI)
Brain Trust Accelerator Fund
C.M.A.K. Solutions Group
Center for the Advancement of Health and Biosciences, CAHB
Collaborative Drug Discovery (CDD)
Dan Zekzer & Associates
Fast Forward LLC
First Island Capital
Foreseeacer Pharmaceuticals, Inc.
GAIA Medical Diagnostics & Interventions
Global Strategic Medical
Kauffman Fellows Finalist
Life Science Nation
Life Science Nation
Magnetic Insight Inc
MSF Capital Advisors
MVP Capital Partners
Office of Cooperative Research (OCR) / Yale University
Oncozyme Pharma Inc
Deva Cell Inc.
Sigma-Tau Pharmaceuticals, Inc.
TriPoint Global Equities
University of California, San Francisco
World Hearing Organization Inc.
Xalud Therapeutics Inc.
Pluristem Therapeutics Inc.
Precision Thoracic LLC
Drake BioBridge Consulting, Inc
Questions, issues or concerns? I'd love to help you!